Alkermes reported positive Phase 2 results for alixorexton, a novel orexin agonist for narcolepsy type 1, showing statistically significant improvements in wakefulness and reductions in excessive daytime sleepiness over six weeks. Although only the middle dose showed a significant decrease in cataplexy frequency, the company plans to refine assessment methods ahead of Phase 3. Alkermes aims to compete with Takeda’s similar candidate, which has reached later development stages. Despite promising efficacy, safety signals such as visual disturbances remain under surveillance. The drug’s once-daily oral dosing could offer a commercial edge against competitors’ more complex regimens.